Upgrade to SI Premium - Free Trial

Voyager Therapeutics (VYGR)

3.04 -0.05 (1.62%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/10/26)

Latest Headlines

H.C. Wainwright Reiterates Buy Rating on Voyager Therapeutics (VYGR) August 27, 2026 7:08 AM - StreetInsider Form SCHEDULE 13G/A Voyager Therapeutics, Filed by: ARMISTICE CAPITAL, LLC August 14, 2026 10:30 AM - SEC Filing Voyager Therapeutics (VYGR) Tops Q2 EPS by 10c August 6, 2026 5:34 PM - StreetInsider Form 8-K Voyager Therapeutics, For: Aug 06 August 6, 2026 4:04 PM - SEC Filing Form 10-Q Voyager Therapeutics, For: Jun 30 August 6, 2026 4:03 PM - SEC Filing Voyager Reports Second Quarter 2026 Financial and Operating Results August 6, 2026 4:01 PM - Globe NewsWire Form SCHEDULE 13G/A Voyager Therapeutics, Filed by: INTEGRATED CORE STRATEGIES (US) LLC July 31, 2026 6:15 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Voyager Therapeutics (VYGR) July 20, 2026 6:52 AM - StreetInsider Form 8-K Voyager Therapeutics, For: Jul 13 July 13, 2026 8:44 AM - SEC Filing Voyager tau gene therapy shows tolerability in 6-month NHP study July 13, 2026 8:04 AM - StreetInsider Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026 July 13, 2026 8:01 AM - Globe NewsWire Voyager to present Alzheimer's gene therapy data at AAIC 2026 June 29, 2026 8:03 AM - StreetInsider Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026 June 29, 2026 8:01 AM - Globe NewsWire Full Article List